北京商报讯（记者 丁宁）11月26日，由中国疾病预防控制中心（中国预防医学科学院）指导，中央广 播电视总台央视网与国家老年大学联合发起的"糖疹联防，稳住血糖"的乐龄健康第一课正式开讲。希望 通过系列化、常态化的健康科普课程，以中老年常见慢病及带状疱疹等感染性疾病为切点，提升健康素 养并呼吁警惕共病风险，唤醒其"主动健康"意识与自我管理能力。 中国疾病预防控制中心慢病和老龄健康管理处处长赖建强表示，"期待这样的新路径，不仅能对提升中 老年慢病人群的健康水平和生活质量有所助益，更会为应对老龄化挑战的公共卫生防线添砖加瓦。" 对此，北京大学第一医院内分泌科主任郭晓蕙呼吁："鉴于糖尿病与带状疱疹之间的共病机制，临床管 理思维亟需从'单独控糖'升级为'共病联防'。在临床管理路径中主动纳入对带状疱疹等共病风险的评估 与预防指导，比如在患者血糖控制稳定时，通过接种疫苗来预防常见的感染性疾病，对糖尿病患者管理 自身基础疾病、减轻感染性疾病的叠加负担，有着积极意义。 面对"糖""疹"共病的恶性循环及治疗局限性，"预防先行"与"医防融合"已成为构筑中老年慢病人群健康 防线的核心战略。 据了解，目前我国正面临每年逾2.3亿糖尿病患 ...

《中国成人疫苗接种健康促进策略专家共识》发布，流感防控成为重点方向 中新网北京11月20日电 近日，我国首个聚焦成人疫苗政策体系，多学科跨领域的专家共识——《中国 成人疫苗接种健康促进策略专家共识》(以下简称《共识》)发布。《共识》由清华大学健康中国研究 院、北京大学公共卫生学院、南方科技大学全科医学院、公共安全科学技术学会公共卫生安全与健康专 业委员会牵头，联合近50位专家学者共同制订。 《共识》聚焦成人疫苗接种的必要性与健康价值，针对我国成人免疫规划短板提出系统性解决方案，其 中流感疫苗接种作为降低人群发病风险、减轻医疗负担的关键举措，被多次提及。 流感等疫苗可预防的疾病给全龄人群带来了沉重的健康负担，在叠加感染的情况下，更带来严重的死亡 风险。《共识》建议，疫苗接种是预防和控制传染病最经济且有效的公共卫生措施，能够降低多种传染 病和部分慢性疾病的发生以及重症和死亡风险。 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 11月10日，在国家疾病预防控制局召开的"秋冬季急性呼吸道传染病防控 ...

2025年11月14日，在广东省预防医学会主办的"2025年疫苗新技术进展与应用培训班"上，全球首款六价轮状病毒 疫苗正式亮相。该疫苗由国药集团中国生物武汉生物制品研究所自主研发，是我国预防用生物制品1类新药，可全 面覆盖G1、G2、G3、G4以及国内主流流行株G8、G9六种血清型，实现了对轮状病毒流行株的全面防护，为破解 5岁以下儿童轮状病毒腹泻防控难题带来新突破。 秋季腹泻高发，轮状病毒成婴幼儿健康"头号威胁" 权威研究发现，轮状病毒感染不仅造成直接疾病负担，还会影响儿童长期生长发育。"儿童早期腹泻可能影响身高 和智力发育，一次中重症腹泻更会使患儿在患病后两个月内的死亡风险增加8.5倍。" 六价疫苗实现技术突破，覆盖流行株且安全性卓越 此次亮相的六价轮状病毒疫苗"武生儿轮宝"彻底改变了现有疫苗的防护格局。作为全球首个覆盖六种血清型的轮 状病毒疫苗，其最突出的优势是精准覆盖了国内主流流行的G8、G9型别，而此前国外上市的单价或五价疫苗均未 涵盖亚洲常见的G8型毒株。 研发团队详细介绍了疫苗的三大技术亮点：采用突破性均质工艺确保病毒颗粒均一性与高稳定性；使用无动物源 性配方且不含防腐剂、抗生素，从源头提升纯净 ...

Core Insights - GSK emphasizes its commitment to health management through a combination of prevention and treatment, showcasing its innovative product pipeline at the 2025 China International Import Expo [1][3][6] Group 1: Innovation and Product Pipeline - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for chronic hepatitis B that aims for "functional cure" [1][3] - The company also introduced a long-acting monoclonal antibody for chronic diseases and a first-in-class antibody-drug conjugate for multiple myeloma, covering various therapeutic areas [1][3] Group 2: Health Management Strategy - GSK is focused on integrating prevention and treatment, aiming to create a comprehensive health management model that spans the entire lifecycle of diseases [3][4] - The company has a long history in hepatitis management, providing innovative solutions from vaccines to antiviral treatments [3] Group 3: Collaboration and Market Strategy - GSK has established partnerships with local companies to enhance the accessibility of its vaccines and support healthcare initiatives in China [5] - The company plans to accelerate its local market strategy, with over 80% of its R&D projects in China aligned with global development, aiming to introduce approximately 18 new products and indications in the next three years [6]

Core Insights - The "Gongxiang Health" seminar focused on the collaborative prevention and control of four major chronic diseases: hypertension, diabetes, chronic obstructive pulmonary disease (COPD), and cancer, aiming for early prevention, detection, intervention, and management [1][2] - The project aims to create a high-quality collaborative innovation model at the city level over the next three years, establishing an integrated closed-loop system for prevention, screening, diagnosis, treatment, rehabilitation, and management [1] - The seminar highlighted the upgraded "medical-prevention integration" approach from Sanming City, which emphasizes health outcome-oriented assessment methods to optimize public health service performance [1] Project Collaboration - The collaboration between Zigong and Sanming projects will enhance management, data sharing, talent exchange, research cooperation, and industry incubation across six key areas [2] - The seminar aims to advance baseline surveys for the four major chronic diseases, develop health profiles for the population, and improve the national digital information platform to provide evidence-based guidelines for chronic disease intervention and policy [2]

Core Viewpoint - The 8th China International Import Expo (CIIE) showcased GSK's commitment to the Chinese market with its innovative health solutions, particularly highlighting the newly approved shingles vaccine, which targets high-risk groups [1][2][3]. Group 1: GSK's Vaccine Innovations - GSK's shingles vaccine, Xinanlis, is the first and only shingles vaccine approved by the NMPA for high-risk adults aged 18 and above [1][3]. - The vaccine's approval for expanded indications aims to protect individuals with immune deficiencies or immunosuppression, reflecting a shift towards proactive immunization across all life stages [1][3]. - GSK emphasizes the integration of vaccine prevention into chronic disease management, particularly for high-risk groups such as those with hypertension, diabetes, and cardiovascular diseases [2][3][11]. Group 2: Market Potential and Growth - The adult vaccine market in China is projected to grow significantly, with the shingles vaccine market expected to reach 5.63 billion yuan by 2025 and exceed 10 billion yuan by 2031 [9]. - With over 500 million chronic disease patients in China, achieving a 5% to 10% vaccination rate could translate to a market size in the hundreds of billions [9][10]. - The increasing prevalence of chronic diseases and an aging population are key drivers for the growth of the adult vaccine market [9]. Group 3: Challenges and Strategies - Despite high awareness of shingles (80%-90%) and vaccine knowledge (60%-80%), the vaccination rate remains low at 1%-2% [5]. - GSK is addressing this "knowledge-action gap" by implementing "vaccine prescriptions" to enhance accessibility and conversion rates for vaccinations [5][6]. - The company is developing a multi-tiered adult vaccine management system, aiming to integrate vaccine management with chronic disease management [6][10]. Group 4: Future Directions - GSK plans to extend its focus from cardiovascular and diabetes management to include other chronic diseases like COPD, promoting a comprehensive approach to disease management [12]. - The company is committed to leveraging its innovative research and development capabilities to enhance public health in China, particularly through the introduction of new vaccines [12].

Core Viewpoint - GSK's Shingrix vaccine has received approval for a new indication in China, expanding its target population to adults aged 18 and above with immunodeficiencies, marking a significant shift in the approach to shingles prevention from elderly management to proactive immunization across the lifespan [1][3][5] Group 1: Market Potential - The domestic shingles vaccine market in China was valued at approximately 3.73 billion yuan in 2022, with projections indicating it could reach 5.63 billion yuan by the end of 2025, reflecting a compound annual growth rate (CAGR) of 16.4% [3][5] - GSK's Shingrix vaccine achieved sales of £3.364 billion (approximately $4.298 billion) in 2024, making it the highest-selling product for the company [3][5] - The approval of the new indication positions GSK strategically in a market projected to exceed 10 billion yuan by 2031, with a 6-year CAGR of 10.1% [5] Group 2: Competitive Landscape - Currently, there are only two approved shingles vaccines in China, with GSK's Shingrix being the only option for the newly approved immunocompromised population [3][4] - GSK's differentiated technological advantage lies in its robust clinical data, which enhances trust among healthcare institutions, particularly in specialized markets such as oncology and transplant centers [4][8] Group 3: Strategic Initiatives - GSK aims to elevate China to its second-largest market globally by 2031, emphasizing the importance of the Chinese vaccine market in its overall strategy [6] - The company is focusing on integrating disease prevention with treatment, aligning with China's health policy shift towards a health-centered approach [6][7] - GSK is exploring innovative payment solutions to improve vaccine accessibility, including potential inclusion in customized commercial health insurance and corporate health benefits [7][8] Group 4: Challenges and Opportunities - The low vaccination rate in China presents a significant challenge, prompting GSK to enhance public awareness through digital platforms and strengthen collaborations with healthcare institutions [7][8] - GSK is committed to building a comprehensive adult vaccination service system and is actively working on integrating vaccination into chronic disease management frameworks [8]

Group 1 - The 17th Health China Forum was held on October 24, focusing on the achievements and policies in health during the 14th Five-Year Plan and looking forward to the 15th Five-Year Plan [1][3][4] - Key speakers included government officials, academicians, and industry leaders discussing the strategic significance of the pharmaceutical industry and the need for high-quality development [5][7][10] - The forum highlighted the importance of a comprehensive food safety regulatory system for special foods, particularly for vulnerable populations [8] Group 2 - The forum emphasized the need for innovation in the pharmaceutical industry, transitioning from application innovation to source innovation, and from local contributions to global responsibilities [7] - A report on the ten-year keywords in health construction was released, including topics like drug procurement, medical insurance reform, and health aging [12] - The importance of integrating basic research, translational research, and industrialization was stressed to ensure that valuable research benefits the public [12][15] Group 3 - Companies like China Resources Sanjiu and Yangtze River Pharmaceutical Group discussed their commitment to quality and the full industry chain in traditional Chinese medicine [19][20] - The launch of the "Health China: Allergic Rhinitis Prevention and Treatment Public Welfare Science Popularization Plan" aims to address the rising prevalence of allergic rhinitis in China [21]

Core Insights - GSK's recombinant shingles vaccine, RZV, has been approved by China's NMPA for use in adults aged 18 and above who are at increased risk of shingles due to known diseases or treatments that cause immunodeficiency or immunosuppression [1][2] - The approval addresses a significant public health issue, as there are approximately 6 million cases of shingles in China each year, with factors like immunodeficiency increasing the risk of infection [1] - This is the first and only recombinant shingles vaccine approved for this high-risk population in China, filling a critical gap in disease prevention [2] Company Strategy - GSK aims to enhance the accessibility of RZV for high-risk groups, recognizing the severe impact shingles can have on their health and quality of life [2] - The company is committed to integrating disease prevention into its corporate strategy, supporting the development of a comprehensive "prevention-treatment" solution throughout the lifecycle of healthcare [2] - GSK's efforts align with China's vision for "Healthy China 2030," contributing to the advancement of immunization initiatives in the country [2] Clinical Evidence - The approval was based on data from six clinical trials conducted in patients aged 18 and older, including those who have recently undergone hematopoietic stem cell transplants, kidney transplants, or are living with blood cancers, solid tumors, or HIV [2]

Core Insights - The Fourth Health Service System Innovation Conference concluded successfully in Beijing, focusing on the integration of health service systems and the exploration of innovative models for health management and prevention [2][32] Group 1: Conference Overview - The conference was co-hosted by several organizations, including the China Pharmaceutical Education Association and the Shanghai Chuangqi Health Development Research Institute, with strategic support from major pharmaceutical companies [2] - Key topics discussed included the integration of medical and preventive services, tiered diagnosis and treatment systems, and the support of the Healthy China strategy [2][3] Group 2: Keynote Speeches - Professor Cai Jiangnan emphasized the importance of summarizing the achievements of the 14th Five-Year Plan and planning for the 15th Five-Year Plan, advocating for a people-centered and sustainable health service system [3] - Professor Liang Wannian highlighted the need for a health-centered integrated health service system, addressing current challenges such as lack of continuity and resilience in healthcare services [6] - Professor Mao Zongfu discussed the impact of DRG/DIP payment reform on healthcare institutions, emphasizing its role in transforming healthcare incentives and promoting strategic purchasing in health insurance [7] Group 3: Roundtable Discussions - A roundtable discussion on tiered diagnosis and treatment emphasized the progress made during the 14th Five-Year Plan, with significant improvements in grassroots service capabilities [15] - Another roundtable focused on the role of technological innovation in enhancing the quality of public hospitals, with participants agreeing that innovation is crucial for future development [19] Group 4: Case Studies and Future Directions - The release of the "2024-2025 China Health Service System Innovation Case Collection" highlighted the structural changes in health service demand due to demographic shifts, advocating for policy recommendations centered on integrated service systems [26] - The conference concluded with a call for continued efforts in integrating health services, promoting tiered diagnosis and treatment, and leveraging technology for better health outcomes [32]